

Effect of Sequential Intrastromal Corneal Ring Segment Implantation and Corneal Collagen Crosslinking in Corneal Ectasia

Chung Young Kim¹, Mee Kum Kim^{1,2}

¹Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

²Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea

Purpose: To assess the clinical efficacy of sequential intrastromal corneal ring segment (ICRS) implantation and corneal crosslinking (CXL) in corneal ectasia.

Methods: This retrospective case series included eight eyes in which both ICRS implantation and CXL had been performed. CXL was performed within 1 month after ICRS implantation. The clinical outcomes (visual acuity, refractive errors, keratometry, and topographic indices) of these patients were compared with those of patients who had undergone only ICRS implantation (eight eyes) or CXL (20 eyes).

Results: Greater improvement in uncorrected visual acuity was observed in the ICRS + CXL group than in the ICRS or CXL alone groups at both 6 ($p = 0.008$) and 12 months ($p = 0.028$). Refractive errors of sphere and spherical equivalent were significantly reduced in both the ICRS ($p = 0.002$ at 6 months, $p = 0.004$ at 12 months) and ICRS + CXL groups ($p < 0.001$ at both 6 and 12 months). Keratometric values including the maximum, minimum, and average were significantly reduced in all 3 groups at postoperative 6 and 12 months; however, the greatest reductions were observed in the ICRS + CXL group (all $p < 0.001$).

Conclusions: ICRS implantation followed by CXL within 1 month seems to be effective, and may be superior to ICRS or CXL alone in improving visual acuity and reducing refractive errors and keratometric values.

Key Words: Cornea, Crosslinking, Intrastromal corneal ring segment, Keratoconus, Post-laser *in situ* keratomileusis ectasia

Keratoconus and post-laser *in situ* keratomileusis (LASIK) ectasia are progressive, non-inflammatory corneal ectasia disorders characterized by progressive corneal thinning that results in corneal protrusion, irregular astig-

matism and visual distortion. Spectacles and rigid contacts lenses are typically used to improve visual acuity [1]. However, for those who cannot tolerate contact lenses, intrastromal corneal ring segments (ICRS) can be implanted to reduce refractive errors and flatten the cornea [2].

Recently, corneal collagen crosslinking (CXL) has also been widely applied to treat ectasia [3]. CXL introduces chemical bonds between corneal collagen fibers, thus enhancing the integrity and mechanical strength of the cornea [4,5]. In this procedure, the cornea is subjected to

Received: July 25, 2019 Final revision: August 16, 2019

Accepted: September 2, 2019

Corresponding Author: Mee Kum Kim, MD, PhD. Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Tel: 82-2-2072-2665, Fax: 82-2-741-3187, E-mail: kmk9@snu.ac.kr

© 2019 The Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

UV-A irradiation after being treated with a photosensitizer (riboflavin). Although the clinical effects of the diverse CXL protocols vary, CXL has been demonstrated to effectively halt the progression of ectasia by stabilizing and strengthening the cornea [3]. However, CXL alone can only reduce refractive errors by less than 3 diopters, which is not sufficient to improve naked visual acuity in very steep corneas with high myopic astigmatism.

ICRS were first introduced as an intervention for myopia [6]. In corneal ectasia, ICRS are implanted at the mid-periphery of the corneal stroma, where they displace the local anterior surface while flattening the central portion of the anterior surface. ICRS implantation has been demonstrated to improve visual acuity by reducing the refractive errors and keratometry in keratoconus [2]. ICRS implantation is regarded as an attractive surgical option because it is minimally invasive and reversible, and also can delay or preclude keratoplasty.

To achieve both visual rehabilitation and corneal stabilization, a combined procedure of ICRS implantation and CXL has been introduced. ICRS implantation flattens the corneal surface but does not prevent the progression of keratoconus; indeed, several reports have described the regression of the beneficial effects of ICRS in long-term follow-up [7-11]. On the other hand, CXL stabilizes the pathologic cornea but does not cause significant visual recovery. The combination of ICRS implantation and CXL has been demonstrated to have synergistic effects in some studies, but a consensus on these effects has not yet been reached [12].

The aim of the present study was to compare the effects of ICRS implantation followed by CXL with those of ICRS implantation or CXL alone on visual, refractive and keratometric outcomes during 12 months of postoperative follow-up.

Materials and Methods

Patients

This retrospective study adhered to the ethical standards of the Declaration of Helsinki and was approved by the institutional review board of Seoul National University College of Medicine, Seoul, South Korea (1907-089-1048). Written informed consent was waived due to the retro-

spective nature of the study. The study included 36 eyes of 34 patients with progressive keratoconus or post-LASIK ectasia who underwent CXL, ICRS implantation or both procedures. The procedures were performed by a single surgeon (MKK) at a single institution (Seoul National University Hospital). The medical records of the 34 patients were retrospectively reviewed. We included eight eyes of eight patients in the ICRS group, 20 eyes of 18 patients in the CXL group and eight eyes of eight patients in the ICRS + CXL group. Patients with preoperative Kmax values greater than 60 diopters or central corneal thickness (CCT) values less than 400 μm were excluded. Patients who had other ocular surface diseases, surgical history or trauma history were also excluded. The data from patients with ICRS implantation only [13] and CXL only [14] were reported previously, and were included in this study for comparison with the ICRS + CXL group.

Clinical evaluation

Preoperative and postoperative examinations included best-corrected visual acuity (BCVA) and uncorrected visual acuity (UCVA) as a logarithm of the minimum angle of resolution, refractive errors determined with an auto kerato-refractometer (KR-8900, Topcon, Tokyo, Japan), and keratometric values including the maximum (Kmax), minimum (Kmin), and average (Kavg) determined by topography (ORBSCAN II, Bausch & Lomb, Rochester, NY, USA). CCT and thinnest corneal thickness (TCT) were measured by anterior segment optical coherence tomography (AS-OCT; Visante OCT, Carl Zeiss Meditec, Dublin, CA, USA). Noncontact specular microscopy (SP-8800, Konan, Hyogo, Japan) was used to measure endothelial cell density in the CXL and ICRS + CXL groups. Preoperative measurements were compared with postoperative measurements at 1, 2 or 3, 6 and 12 months for intra-group analyses. The measured values were also compared among the groups at each time point for inter-group analyses.

ICRS implantation

The implantation axis and depth of the ICRS (Intacs, Addition Technology, Sunnyvale, CA, USA) were determined by preoperative topography (ORBSCAN II) and AS-OCT (Visante OCT) based on the nomogram defined by the manufacturer. The depth of incision was set as 80%

of the corneal thickness at the incision site, which was measured by AS-OCT. In all cases, two Intacs® with an inner diameter of 6.0 mm were inserted symmetrically. The detailed surgical procedure was reported in our previous study [13].

In brief, the center of the cornea was marked with an 11-mm zone marker (Frimen, Jiangsu, China) and a sinsky hook. The incision site was marked with reference to the corneal center, and a corneal incision was made with a diamond knife. Stromal pockets were created with a pocket hook, and a symmetric glide was inserted to enlarge the pockets. Vacuum centering guides were applied to fix the eye, and dissectors were inserted into the pockets with a vacuum of 450 mBar. The dissectors were used to create stromal tunnels both clockwise and counterclockwise. The vacuum centering guides were then removed and the ICRS were inserted. The incision site was repaired with a 10-0 nylon suture. The depth of insertion was confirmed through an intraoperative portable slit-lamp examination. A silicone hydrogel bandage contact lens (ACUVUE OASYS, Johnson & Johnson Vision Care, Jacksonville, FL, USA) was applied, and was maintained with topical 0.5% moxifloxacin and 1% prednisolone four times per day for seven days. In the combined group, crosslinking was performed after an average interval of 41.8 ± 20.2 days.

Crosslinking

The detailed surgical procedure for CXL was reported previously [14]. The corneal epithelium was peeled off and the CCT (≥ 325 μm) was determined by pachymetry (Pocket II, Quantel Medical, Bozeman, MT, USA). Then, a retention ring (8.0 mm in diameter, Frimen) was applied to the epi-off corneal surface, and 0.1% isotonic riboflavin with dextran-free hydroxypropyl methylcellulose (VibeX Rapid, Avedro, Waltham, MA, USA) was continuously applied for ten minutes within the retention ring. Then, a trephined (inner diameter, 8.5 mm) silicone hydrogel bandage contact lens (ACUVUE OASYS) was applied to protect the limbus from UV irradiation. UV-A irradiation (Avedro) was applied at a pulsing (1 second on/off) intensity of 30 mW/cm^2 at a wavelength of 365 nm for eight minutes, resulting in a cumulative dose of 7.2 J/cm^2 . After irrigation, the silicone hydrogel bandage contact lens was applied for seven days with topical 0.5% moxifloxacin and 1% prednisolone four times per day.

Statistical analysis

Statistical analysis was performed with IBM SPSS Statistics ver. 22 (IBM Corp., Armonk, NY, USA). Paired *t*-tests were used to compare each of the baseline parameters with the follow-up measurements in intra-group analyses. For inter-group analyses of continuous variables, the Kruskal-Wallis test was performed, and Bonferroni correction was applied for the post hoc test. The data are presented as the mean \pm standard deviation, and statistical significance was established if $p < 0.05$ (paired *t*-test) or $p < 0.017$ (Kruskal-Wallis test). After Bonferroni correction, statistical values are considered significant only when $p < 0.017$ in the Kruskal-Wallis test.

Results

In this study, 36 eyes from 34 patients were analyzed over a mean postoperative follow-up period of 12.2 ± 3.4 months. The baseline characteristics of each study group are shown in Table 1. The mean age of all the subjects was 31.0 ± 10.3 years, and patients in the ICRS + CXL group were significantly older than patients in the other groups at the time of operation ($p = 0.005$). Diagnoses of keratoconus and post-LASIK ectasia were made in 30 and 6 eyes, respectively; however, there were no significant demographic differences between the groups. The BCVA, refractive errors, keratometric values (Kmax, Kmin, and Kavg) and astigmatism did not differ significantly among the groups. The UCVA was lower in the ICRS + CXL group than in the other groups ($p < 0.001$). The CCT exhibited a marginally significant difference among the groups ($p = 0.041$), while the TCT did not. Endothelial cell density measurements were not routinely performed in the ICRS group, and did not differ between the CXL and ICRS + CXL groups.

Table 2 displays the intra-group changes in each clinical parameter between the preoperative measurement and the postoperative measurements at 6 and 12 months. Table 3 and Fig. 1A, 1B, 2A-2C, 3A-3D display the inter-group comparisons of each clinical parameter at postoperative 6 and 12 months. The intra-group analysis revealed that the BCVA of the CXL group had significantly improved after 12 months ($p = 0.05$) (Table 2) and the UCVA of the ICRS + CXL group had significantly improved after 6 months

Table 1. Baseline characteristics of each group

Parameter	ICRS	CXL	ICRS + CXL	Total	<i>p</i> -value
No. of eyes	8	20	8	36	
Sex (male : female)	5 : 3 (62.5 : 37.5)	14 : 4 (77.7 : 22.3)	3 : 5 (37.5 : 32.5)	22 : 12 (64.7 : 35.3)	0.317*
Age (yr)	26.5 ± 5.6	28.0 ± 7.3	42.8 ± 11.8	31.0 ± 10.3	0.005 ^{†‡}
Diagnosis	Keratoconus: 6 (75) Post-LASIK ectasia: 2 (25)	Keratoconus: 20 (100)	Keratoconus: 4 (50) Post-LASIK ectasia: 4 (50)	Keratoconus: 30 (83) Post-LASIK ectasia: 6 (17)	0.186*
BCVA (logMAR)	0.39 ± 0.27	0.42 ± 0.43	0.47 ± 0.20	0.43 ± 0.34	0.521 [†]
UCVA (logMAR)	0.89 ± 0.31	0.81 ± 0.38	1.29 ± 0.27	0.76 ± 0.51	<0.001 ^{†‡}
Sphere (D)	-7.19 ± 3.53	-7.40 ± 2.80	-8.78 ± 2.69	-7.67 ± 2.95	0.590 [†]
Cylinder (D)	-4.59 ± 2.30	-4.81 ± 1.36	-4.97 ± 3.54	-4.80 ± 2.22	0.924 [†]
SE (D)	-9.39 ± 3.43	-9.81 ± 2.93	-11.27 ± 3.08	-10.07 ± 3.10	0.425 [†]
Kmax (D)	51.78 ± 7.24	52.20 ± 4.32	53.29 ± 3.16	52.15 ± 4.69	0.516 [†]
Kmin (D)	46.23 ± 5.27	46.50 ± 2.18	48.48 ± 3.07	46.82 ± 3.29	0.238 [†]
Kavg (D)	49.00 ± 6.05	49.35 ± 3.06	50.88 ± 2.92	49.48 ± 3.79	0.287 [†]
Astig (D)	5.55 ± 3.70	5.71 ± 3.07	4.84 ± 2.18	5.33 ± 2.89	0.898 [†]
CCT (μm)	455.1 ± 47.2 (Topo)	492.1 ± 39.1	469.1 ± 31.1	480.8 ± 40.7	0.041 [†]
TCT (μm)	435.9 ± 51.4 (Topo)	466.6 ± 37.1	442.3 ± 39.0	456.4 ± 41.4	0.069 [†]
ECD (cells/cm ²)	NA	2,731 ± 279	2,628 ± 310	2,668 ± 254	0.689 [†]

Values are presented as the mean ± standard deviation or number (%).

ICRS = intrastromal corneal ring segment; CXL = corneal crosslinking; LASIK = laser *in situ* keratomileusis; BCVA = best-corrected visual acuity; logMAR = logarithm of minimum angle of resolution; UCVA = uncorrected visual acuity; D = diopters; SE = spherical equivalents; Kmax = maximum keratometry; Kmin = minimum keratometry; Kavg = average keratometry; Astig = astigmatism; CCT = central corneal thickness; TCT = thinnest corneal thickness; ECD = endothelial cell density; NA = not applicable.

*Chi-square tests between groups; [†]Kruskal-Wallis tests among groups; [‡]Statistical significance was established if *p* < 0.017.




Fig. 1. Inter-group analyses of (A) best-corrected visual acuity (BCVA) and (B) uncorrected visual acuity (UCVA) changes in the intrastromal corneal ring segment (ICRS) group, corneal crosslinking (CXL) group, and ICRS plus sequential CXL group (ICRS + CXL) at each postoperative follow-up. logMAR = logarithm of minimum angle of resolution. *p*-values from Kruskal-Wallis tests for inter-group analyses at each follow-up are shown.

Table 2. Intra-group time-dependent changes in clinical parameters at postoperative 6 and 12 months

Parameter	ICRS			CXL			ICRS + CXL		
	6 mon	12 mon	<i>p</i> -value	6 mon	12 mon	<i>p</i> -value	6 mon	12 mon	<i>p</i> -value
Δ BCVA (logMAR)	0.05 ± 0.27	-0.03 ± 0.11	0.694* 0.502†	-0.13 ± 0.43	-0.14 ± 0.40	0.074* 0.050†	-0.00 ± 0.24	-0.05 ± 0.29	0.992* 0.724†
Δ UCVA (logMAR)	0.39 ± 0.62	0.46 ± 0.48	0.227* 0.075†	0.00 ± 0.15	-0.04 ± 0.16	0.979* 0.635†	-0.48 ± 0.17	-0.65 ± 0.49	0.003** 0.313†
Δ Sphere (D)	4.86 ± 2.43	4.68 ± 2.77	0.002** 0.004†	-0.96 ± 2.48	-0.42 ± 2.87	0.741* 0.245†	7.37 ± 3.52	8.46 ± 2.73	<0.001** <0.001†
Δ Cylinder (D)	0.00 ± 2.38	-0.38 ± 3.34	1.000* 0.786†	-0.50 ± 2.02	-0.38 ± 3.03	0.654* 0.028†	1.34 ± 3.68	1.27 ± 1.86	0.336* 0.151†
Δ SE (D)	4.86 ± 1.83	4.50 ± 3.27	<0.001** 0.011†	-1.21 ± 3.22	-0.60 ± 4.05	0.841* 0.076†	8.04 ± 3.00	9.10 ± 2.44	0.001** <0.001†
Δ Kmax (D)	-5.67 ± 4.14	-5.85 ± 4.46	0.011** 0.024†	-1.15 ± 1.88	-1.33 ± 1.30	0.015** <0.001†	-7.73 ± 1.43	-8.10 ± 1.26	<0.001** <0.001†
Δ Kmin (D)	-5.00 ± 3.15	-4.67 ± 2.53	0.006** 0.006†	-0.28 ± 1.16	-0.34 ± 0.89	0.308* 0.113†	-7.30 ± 1.87	-7.78 ± 1.74	<0.001** 0.001†
Δ Kavg (D)	-5.33 ± 3.42	-5.26 ± 3.27	0.006** 0.011†	-0.72 ± 1.43	-0.84 ± 1.05	0.045** 0.003†	-7.51 ± 1.39	-7.94 ± 0.91	<0.001** <0.001†
Δ Astig (D)	-0.67 ± 2.69	-1.18 ± 3.13	0.534* 0.398†	-0.90 ± 1.27	-1.00 ± 0.78	0.007** <0.001†	-0.48 ± 1.86	-0.30 ± 2.50	0.495* 0.781†
Δ CCT (μm)	20.6 ± 34.1	5.3 ± 48.2	0.198* 0.797†	-10.1 ± 17.8	-10.7 ± 17.0	0.027** 0.019†	12.1 ± 18.8	27.7 ± 15.5	0.112* 0.037†
Δ TCT (μm)	19.1 ± 61.4	-15.0 ± 34.3	0.479* 0.334†	-10.7 ± 12.8	-8.4 ± 17.0	0.003** 0.059†	17.0 ± 29.8	25.2 ± 16.0	0.151* 0.050†
Δ ECD (cells/cm ²)	NA	NA	NA	-193 ± 450	-98.7 ± 387	0.078* 0.392†	-60.5 ± 192	-249 ± 285	0.402* 0.122†

Values are presented as the mean ± standard deviation.

ICRS = intrastromal corneal ring segment; CXL = corneal crosslinking; BCVA = best-corrected visual acuity; logMAR = logarithm of minimum angle of resolution; UCVA = uncorrected visual acuity; D = diopters; SE = spherical equivalents; Kmax = maximum keratometry; Kmin = minimum keratometry; Kavg = average keratometry; Astig = astigmatism; CCT = central corneal thickness; TCT = thinnest corneal thickness; ECD = endothelial cell density; NA = not applicable.

*Paired *t*-tests between the preoperative measurements and the measurements at 6 and 12 months, respectively, in each group; †Statistical significance was established if *p* < 0.05.

(*p* = 0.003) (Table 2) compared with the preoperative level. The inter-group analysis demonstrated that the improvement in the UCVA (Δ UCVA) was greater in the ICRS + CXL group than in the other two groups at both 6 (*p* = 0.008) and 12 months (*p* = 0.028) (Table 3 and Fig. 1B). Spherical and spherical equivalent refractive errors were significantly reduced in both the ICRS group (*p* = 0.002 at 6 months, *p* = 0.004 at 12 months) (Table 2) and the ICRS + CXL group (*p* < 0.001 at both 6 and 12 months) (Table 2), but not in the CXL group. The absolute reductions (Δ) of spheres and spherical equivalents were the greatest in the ICRS + CXL group at 6 and 12 months (all *p* < 0.001) (Ta-

ble 3 and Fig. 2). The CXL group exhibited significant reduction of cylinders at 12 months (*p* = 0.028) (Table 2). However, the reduction of cylinders did not differ significantly among the three groups (*p* = 0.554) (Table 3 and Fig. 2B).

Kmax and Kavg were significantly reduced in all 3 groups at postoperative 6 and 12 months (Table 2). Kmin was also significantly reduced in the ICRS and ICRS + CXL groups over time (Table 2). The absolute reductions in Kmax, Kmin, and Kavg were greater in the ICRS + CXL group than in the other groups (all *p* < 0.001) (Table 3 and Fig. 3). However, in the ICRS + CXL group, the abso-




Fig. 2. Inter-group analyses of (A) sphere, (B) cylinder, and (C) spherical equivalent changes in the intrastromal corneal ring segment (ICRS) group, corneal crosslinking (CXL) group, and ICRS plus sequential CXL group (ICRS + CXL) at each follow-up. D = diopters. *p*-values from Kruskal-Wallis tests for inter-group analyses at each follow-up are shown.

lute reductions (Δ) in K_{max} , K_{min} , and K_{avg} did not change significantly from 6 months to 12 months ($p > 0.05$) (Table 2). Meanwhile, the topographic reduction of astigmatism was only significant in the CXL group ($p = 0.007$ at 6 months, $p < 0.001$ at 12 months) (Table 2), although it did not differ significantly from those in the other groups (Table 3 and Fig. 3D).

CCT and TCT were reduced by approximately $10 \mu\text{m}$ in the CXL group (CCT: $p = 0.027$ at 6 months, $p = 0.019$ at 12 months; TCT: $p = 0.003$ at 6 months) (Table 2). On the contrary, both the CCT and TCT had increased in the ICRS + CXL group at 12 months ($p = 0.037$ and 0.050 , respectively) (Table 2). These changes in corneal thickness differed significantly among the three groups at 6 months, but not at 12 months (CCT, $p = 0.012$ and 0.040 ; TCT, $p = 0.012$ and 0.023 at 6 and 12 months; respectively) (Table 3). Endothelial cell density did not exhibit significant changes in intra- or inter-group analyses.

Complications related to the operation and postoperative status are listed in Table 4. A patient in the ICRS group developed herpes keratitis and was successfully treated

with topical acyclovir and oral valaciclovir for one month without a remaining corneal lesion. In the CXL group, there was a single case of delayed wound healing, which spontaneously resolved in 14 days through conservative treatment with artificial tears. There were some complications in the ICRS + CXL group. One patient experienced bacterial keratitis seven days after CXL. After two weeks of topical moxifloxacin instillation, the infection resolved with no definite sequelae. Two patients exhibited epithelial ingrowth requiring a surgical procedure to remove the lesion. In the first case, the epithelial ingrowth was identified seven weeks after CXL at the incision site of ICRS implantation in a keratoconus patient. The epithelial ingrowth was surgically removed at the stromal level, and no further ingrowth was identified. In the second case, the epithelial ingrowth was identified three weeks after CXL at the temporal LASIK flap margin in a post-LASIK ectasia patient. During the epithelial peeling step of the CXL procedure, the flap displayed mild shrinkage with gutters, so a suture was added to tighten the flap. However, a shallow epithelial ingrowth appeared at the flap margin, so this ingrowth

Table 3. Inter-group comparison of changes in clinical parameters at postoperative 6 and 12 months among the three groups

Parameter	6 mon				12 mon			
	ICRS	CXL	ICRS + CXL	<i>p</i> -value	ICRS	CXL	ICRS + CXL	<i>p</i> -value
Δ BCVA (logMAR)	0.05 ± 0.27	-0.13 ± 0.43	-0.00 ± 0.24	0.727*	-0.03 ± 0.11	-0.14 ± 0.40	-0.05 ± 0.29	0.910†
Δ UCVA (logMAR)	0.39 ± 0.62	0.00 ± 0.15	-0.48 ± 0.17	0.008**	0.46 ± 0.48	-0.04 ± 0.16	-0.65 ± 0.49	0.028†
Δ Sphere (D)	4.86 ± 2.43	-0.96 ± 2.48	7.37 ± 3.52	<0.001**	4.68 ± 2.77	-0.42 ± 2.87	8.46 ± 2.73	<0.001†**
Δ Cylinder (D)	0.00 ± 2.38	-0.50 ± 2.02	1.34 ± 3.68	0.328*	-0.38 ± 3.34	-0.38 ± 3.03	1.27 ± 1.86	0.554†
Δ SE (D)	4.86 ± 1.83	-1.21 ± 3.22	8.04 ± 3.00	<0.001**	4.50 ± 3.27	-0.60 ± 4.05	9.10 ± 2.44	<0.001†**
Δ Kmax (D)	-5.67 ± 4.14	-1.15 ± 1.88	-7.73 ± 1.43	<0.001**	-5.85 ± 4.46	-1.33 ± 1.30	-8.10 ± 1.26	<0.001†**
Δ Kmin (D)	-5.00 ± 3.15	-0.28 ± 1.16	-7.30 ± 1.87	<0.001**	-4.67 ± 2.53	-0.34 ± 0.89	-7.78 ± 1.74	<0.001†**
Δ Kavg (D)	-5.33 ± 3.42	-0.72 ± 1.43	-7.51 ± 1.39	<0.001**	-5.26 ± 3.27	-0.84 ± 1.05	-7.94 ± 0.91	<0.001†**
Δ Astig (D)	-0.67 ± 2.69	-0.90 ± 1.27	-0.48 ± 1.86	0.794*	-1.18 ± 3.13	-1.00 ± 0.78	-0.30 ± 2.50	0.408†
Δ CCT (μm)	20.6 ± 34.1	-10.1 ± 17.8	12.1 ± 18.8	0.012**	5.3 ± 48.2	-10.7 ± 17.0	27.7 ± 15.5	0.040†
Δ TCT (μm)	19.1 ± 61.4	-10.7 ± 12.8	17.0 ± 29.8	0.012**	-15.0 ± 34.3	-8.4 ± 17.0	25.2 ± 16.0	0.023†
Δ ECD (cells/cm ²)	NA	-193 ± 450	-60.5 ± 192	0.595*	NA	-98.7 ± 387	-249 ± 285	0.215†

Values are presented as the mean ± standard deviation.

ICRS = intrastromal corneal ring segment; CXL = corneal crosslinking; BCVA = best-corrected visual acuity; logMAR = logarithm of minimum angle of resolution; UCVA = uncorrected visual acuity; D = diopters; SE = spherical equivalents; Kmax = maximum keratometry; Kmin = minimum keratometry; Kavg = average keratometry; Astig = astigmatism; CCT = central corneal thickness; TCT = thinnest corneal thickness; ECD = endothelial cell density; NA = not applicable.

**Kruskal-Wallis tests among the three groups at 6 and 12 months, respectively; †Statistical significance was established if *p* < 0.017.

was surgically removed with additional sutures. No further recurrence was noticed in this patient.

Discussion

In this study, ICRS implantation followed by CXL within one month seemed to reduce refractive errors and keratometric values and improve UCVA to a degree that was comparable to or greater than that of ICRS implantation or CXL alone. The reduction effect seemed to be stabilized 6 months after ICRS + CXL treatment.

In a recent meta-analysis, no significant difference in refractive or keratometric outcomes was found between ICRS implantation and ICRS + CXL treatment [12]. In the same meta-analysis, ICRS + CXL had better effects than ICRS implantation alone on corrected distant visual acuity, but not on uncorrected distant visual acuity. CXL is known to effectively prohibit the progression of keratoconus. Meanwhile, ICRS implantation is known to flatten the cornea and substantially reduce refractive errors, resulting in visual improvement. However, some studies have

demonstrated that the effects of ICRS implantation diminish during long-term follow-up, and ICRS implantation itself is not sufficient to prevent ectatic progression [15]. Therefore, sequential ICRS implantation and CXL is an attractive treatment option for corneal ectasia, as CXL may not only prohibit the progression of corneal ectasia, but also prolong the effects of ICRS implantation by stabilizing the cornea in the flattened state.

We previously reported that accelerated CXL and conventional CXL had comparable outcomes [14]. As expected, when we combined ICRS implantation with the same accelerated CXL protocol in the present study, we observed visual improvement and reduced refractive errors. Although a meta-analysis found no difference among the three methods we analyzed, the authors used different methods of CXL, which may have affected the final outcomes in terms of visual acuity or refraction. Surprisingly, we found that the UCVA was better in the CXL group than in the ICRS + CXL group at 6 and 12 months (Fig. 1B). This may have been due to the fact that the preoperative UCVA was worse in the ICRS + CXL group than in the CXL group. Irregular astigmatism or optical aberrations




Fig. 3. Inter-group analyses of corneal topographic changes in (A) maximum keratometry (Kmax), (B) minimum keratometry (Kmin), (C) average keratometry (Kavg), and (D) astigmatism in the intrastromal corneal ring segment (ICRS) group, corneal crosslinking (CXL) group, and ICRS plus sequential CXL group (ICRS + CXL) at each postoperative follow-up. D = diopters. *p*-values from Kruskal-Wallis tests for inter-group analyses at each follow-up are shown.

Table 4. Complications in each group

Classification	Prevalence (%)
ICRS group	
Herpes keratitis	1 (12.5)
CXL group	
Delayed wound healing	1 (5.0)
ICRS + CXL group	
Epithelial ingrowth	2 (25.0)
Bacterial keratitis	1 (12.5)

ICRS = intrastromal corneal ring segment; CXL = corneal crosslinking.

tions induced by the insertion of the ICRS may be other plausible reasons for the lower UCVA in the ICRS + CXL

group than in the CXL group. However, in the intra-group analysis, the greatest improvement in UCVA from the preoperative value (Δ UCVA) was observed in the ICRS + CXL group (Table 2, 3), suggesting that the combined surgery had synergistic efficacy. Taken together with the fact that the greatest reductions in spherical equivalents, Kmax and Kavg values were observed in the ICRS + CXL group, these results may suggest that ICRS + CXL is a preferable option for improving the UCVA in patients with severe myopic changes due to steep and ectatic corneas.

The optimal sequence of and interval between ICRS implantation and CXL is controversial. A comparative study indicated that ICRS implantation followed by CXL was more effective than the reverse order [9]. Stabilizing the flattened cornea may be more effective than flattening the

stabilized cornea in terms of preventing ectatic progression and improving visual acuity. Theoretically, flattening the ectatic cornea before CXL may have the maximal flattening effect. For this reason, we first performed ICRS implantation to flatten the ectatic cornea, and then performed CXL to strengthen the flattened cornea. In terms of the interval between the procedures, studies with same-day, 3- or 6-month intervals have had comparable clinical results, even though the procedures were performed in different sequences [9,16,17]. Thus, there is no consensus on the ideal sequence or interval. A recent meta-analysis demonstrated that simultaneous ICRS implantation and CXL may provide better outcomes than staged protocols for corneal shape improvement, but not for visual improvement [18]. Prospective studies with well-organized, homogenous protocols are required to establish the optimal sequence and interval.

In the ICRS and ICRS + CXL groups, the BCVA had not significantly improved after 6 or 12 months. Only the CXL group demonstrated significant improvement in the BCVA at 12 months. Our measurement of BCVA was based on the correction of refractive errors determined by an auto kerato-refractometer. In keratoconus or corneal ectasia, image deformation is inevitable, and resultant aberrations at the retinal plane can interfere with autorefractometry measurements. In a recent study comparing manifest refraction and autorefractometry in keratoconus, significantly superior corrected visual acuity was achieved by manifest refraction [19]. Most of the studies discussed in this report were based on manifest refraction. Thus, our BCVA data were limited by the fact that vision was corrected only by automated refraction. However, the UCVA significantly improved over time compared with the preoperative level in the ICRS + CXL group, suggesting that reduced refractive errors combined with CXL may contribute to visual improvement.

Significant differences in corneal thickness changes were observed among the groups. The central and TCT decreased significantly in the CXL group, but not in the ICRS group. However, both of these parameters increased significantly in the ICRS + CXL group; thus, the combination of ICRS implantation and CXL may have resulted in corneal thickening. In the ICRS group, 2 months after implantation, the central and TCT values had increased by 18.5 and 11.1 μm , respectively. However, these parameters continuously decreased after then and there was no signifi-

cant difference after 12 months. In the ICRS + CXL group, the corneal thickness values at 2 months were similar to those of the ICRS group; however, the further decrease in thickness after 2 months were much smaller. This phenomenon may be due to the stabilizing effect of CXL, which increases the corneal rigidity and corneal resistance to thinning. Further studies on the histopathology of the cornea after the procedure and more detailed AS-OCT examinations are required.

In the CXL protocol we used, the corneal epithelium was peeled off for riboflavin application and UV irradiation of the stroma. In cases of epithelial ingrowth, epithelial cells may have entered through the previous ICRS incision site during the peeling step of CXL, due to incomplete wound healing in one month. The epithelial ingrowth in the margins of the LASIK flap in one case may have been induced by damage to the flap margin during the epithelial peeling. Therefore, highly delicate epithelial peeling is required during the CXL procedure, especially following ICRS surgery. As an alternative, trans-epithelial CXL can be attempted after ICRS implantation.

ICRS implantation and CXL are indicated for the mild to moderate stages of corneal ectasia, and are able to delay keratoplasty. Late-stage ectasia requires graft surgeries such as deep anterior lamellar keratoplasty or penetrating keratoplasty. Previous studies comparing ICRS implantation with deep anterior lamellar keratoplasty or penetrating keratoplasty have indicated that graft surgery is superior to ICRS implantation [13,20]. However, ICRS implantation is still an effective treatment, and is regarded as an alternative to graft surgery. Combined ICRS + CXL treatment has not yet been compared with graft surgery. Considering the side effects, cost and recovery period of graft surgery, ICRS implantation with CXL could be an attractive alternative. Future studies comparing graft surgery with the combined procedure are needed.

Our study had several limitations, mostly inherent in its retrospective design, aside from the small sample size. Decisions on protocols were based on preoperative status, so the study was susceptible to selection biases. The preoperative age was greater and the UCVA was worse in the ICRS + CXL group than in the other groups, which may have affected the postoperative outcomes. Thus, we re-analyzed the outcomes after adjusting for age by removing two patients who were over fifty years old from the ICRS + CXL group (Supplemental Table 1). After this adjust-

ment, the mean age of the ICRS + CXL group was 38.3 ± 9.3 years and the UCVA was 1.23 ± 0.25 logarithm of the minimum angle of resolution. Statistical analysis revealed that the groups did not differ significantly in age after this adjustment ($p = 0.035$), but the UCVA was still significantly worse in the ICRS + CXL group than in the other groups ($p < 0.001$) (Supplemental Table 1). However, the UCVA improvement (Δ UCVA) and the reductions in spherical equivalent, Kmax, Kmin, and Kavg (Δ SE or K) were still the greatest in the ICRS + CXL group (Supplemental Table 1). Therefore, age did not seem to affect the final outcomes significantly.

Thus, this study demonstrated the efficacy of sequential ICRS (Intacs) implantation followed by CXL within one month. Likewise, in an age-matched prospective study comparing ICRS and ICRS (Keraring) + CXL [21], the ICRS + CXL group generally exhibited better clinical outcomes. Nevertheless, more meticulously controlled studies with larger samples are required for stronger validity. Still, we believe that we adequately compared the clinical outcomes of the three procedures and proposed possible explanations for the better results of the combined procedure.

In conclusion, our preliminary study demonstrated that ICRS implantation followed by CXL within one month may be effective and superior to ICRS or CXL alone in reducing refractive errors and keratometric values and improving the UCVA after 12 months of follow-up.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Supplemental Material

Supplemental Table 1 is available from: <https://doi.org/10.3341/kjo.2019.0088>.

References

1. Parker JS, van Dijk K, Melles GR. Treatment options for advanced keratoconus: a review. *Surv Ophthalmol* 2015;60:459-80.
2. Rabinowitz YS. Intacs for keratoconus. *Curr Opin Ophthalmol* 2007;18:279-83.
3. Raiskup F, Theuring A, Pillunat LE, Spoerl E. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. *J Cataract Refract Surg* 2015;41:41-6.
4. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. *Exp Eye Res* 1998;66:97-103.
5. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol* 2003;135:620-7.
6. Burris TE. Intrastromal corneal ring technology: results and indications. *Curr Opin Ophthalmol* 1998;9:9-14.
7. Ibrahim O, Elmassry A, Said A, et al. Combined femtosecond laser-assisted intracorneal ring segment implantation and corneal collagen cross-linking for correction of keratoconus. *Clin Ophthalmol* 2016;10:521-6.
8. Cakir H, Pekel G, Perente I, Genc S. Comparison of intrastromal corneal ring segment implantation only and in combination with collagen crosslinking for keratoconus. *Eur J Ophthalmol* 2013;23:629-34.
9. Coskunseven E, Jankov MR 2nd, Hafezi F, et al. Effect of treatment sequence in combined intrastromal corneal rings and corneal collagen crosslinking for keratoconus. *J Cataract Refract Surg* 2009;35:2084-91.
10. Legare ME, Iovieno A, Yeung SN, et al. Intacs with or without same-day corneal collagen cross-linking to treat corneal ectasia. *Can J Ophthalmol* 2013;48:173-8.
11. Liu XL, Li PH, Fournie P, Malecaze F. Investigation of the efficiency of intrastromal ring segments with cross-linking using different sequence and timing for keratoconus. *Int J Ophthalmol* 2015;8:703-8.
12. Benoist d'Azy C, Pereira B, Chiambaretta F, Dutheil F. Efficacy of different procedures of intra-corneal ring segment implantation in keratoconus: a systematic review and meta-analysis. *Transl Vis Sci Technol* 2019;8:38.
13. Kim JA, Kim DH, Wee WR, Kim MK. Clinical results of intacs(R) ring implantation in keratoconus or keratectasia. *J Korean Ophthalmol Soc* 2015;56:499-508.
14. Kim CY, Kim MK. Effect of the retention ring-assisted continuous application of riboflavin in pulsed-light accelerated corneal collagen cross-linking on the progression of keratoconus. *BMC Ophthalmol* 2019;19:72.
15. Park J, Gritz DC. Evolution in the use of intrastromal corneal ring segments for corneal ectasia. *Curr Opin Ophthalmol* 2013;24:296-301.

16. Kilic A, Kamburoglu G, Akinci A. Riboflavin injection into the corneal channel for combined collagen crosslinking and intrastromal corneal ring segment implantation. *J Cataract Refract Surg* 2012;38:878-83.
17. Saelens IE, Bartels MC, Bleyen I, Van Rij G. Refractive, topographic, and visual outcomes of same-day corneal cross-linking with Ferrara intracorneal ring segments in patients with progressive keratoconus. *Cornea* 2011;30:1406-8.
18. Hashemi H, Alvani A, Seyedian MA, et al. Appropriate sequence of combined intracorneal ring implantation and corneal collagen cross-linking in keratoconus: a systematic review and meta-analysis. *Cornea* 2018;37:1601-7.
19. Soeters N, Muijzer MB, Molenaar J, et al. Autorefraction versus manifest refraction in patients with keratoconus. *J Refract Surg* 2018;34:30-4.
20. Ozerturk Y, Sari ES, Kubaloglu A, et al. Comparison of deep anterior lamellar keratoplasty and intrastromal corneal ring segment implantation in advanced keratoconus. *J Cataract Refract Surg* 2012;38:324-32.
21. Elsaftawy HS, Ahmed MH, Saif MY, Mousa R. Sequential intracorneal ring segment implantation and corneal transepithelial collagen cross-linking in keratoconus. *Cornea* 2015;34:1420-6.

Supplemental Table 1. Baseline and repeated intra- and inter-group analyses after age adjustment (removal of 2 patients over the age of fifty from the ICRS + CXL group)

Parameter	Preop	<i>p</i> -value*	Parameter	6 mon 12 mon	<i>p</i> -value†	<i>p</i> -value‡
BCVA (logMAR)	0.49 ± 0.22	0.552	Δ BCVA (logMAR)	-0.07 ± 0.21 -0.11 ± 0.25	0.593 0.098	0.808 0.902
UCVA (logMAR)	1.23 ± 0.25	<0.001§	Δ UCVA (logMAR)	-0.43 ± 0.14 -0.30 ± 0.00	0.137 0.748	0.015§ 0.065
Sphere (D)	-8.46 ± 1.57	0.707	Δ Sphere (D)	3.75 ± 1.84 7.56 ± 1.46	<0.001§ 0.001§	<0.001§ <0.0001§
Cylinder (D)	-5.95 ± 4.98	0.817	Δ Cylinder (D)	2.46 ± 3.31 2.03 ± 1.86	0.242 0.168	0.111 0.244
SE (D)	-11.43 ± 2.25	0.363	Δ SE (D)	7.98 ± 2.24 8.60 ± 1.16	<0.001§ 0.001§	<0.001§ <0.001§
Kmax (D)	52.95 ± 3.54	0.721	Δ Kmax (D)	-7.73 ± 1.98 -7.48 ± 0.69	<0.001§ <0.001§	<0.001§ 0.001§
Kmin (D)	48.25 ± 2.39	0.297	Δ Kmin (D)	-7.25 ± 1.98 -7.73 ± 2.03	0.003§ <0.001§	<0.001§ <0.001§
Kavg (D)	50.60 ± 2.86	0.488	Δ Kavg (D)	-7.34 ± 1.48 -7.60 ± 0.96	0.001§ <0.001§	<0.001§ <0.001§
Astig (D)	4.72 ± 1.86	0.933	Δ Astig (D)	-0.22 ± 2.00 -0.28 ± 2.46	0.054 0.027	0.700 0.335
CCT (μm)	470.0 ± 30.5	0.044	Δ CCT (μm)	17.8 ± 18.3 30.0 ± 18.2	0.469 0.736	0.029 0.074
TCT (μm)	448.7 ± 34.0	0.118	Δ TCT (μm)	21.7 ± 33.7 18.7 ± 11.2	0.642 0.785	0.022 0.069
ECD (cells/cm ²)	2,684 ± 341	0.828	Δ ECD (cells/cm ²)	-44.7 ± 198 -62.3 ± 171	0.017 0.064	0.611 0.911

Values are presented as the mean ± standard deviation.

ICRS = intrastromal corneal ring segment; CXL = corneal crosslinking; BCVA = best-corrected visual acuity; logMAR = logarithm of minimum angle of resolution; UCVA = uncorrected visual acuity; D = diopters; SE = spherical equivalents; Kmax = maximum keratometry; Kmin = minimum keratometry; Kavg = average keratometry; Astig = astigmatism; CCT = central corneal thickness; TCT = thinnest corneal thickness; ECD = endothelial cell density.

*Kruskal-Wallis tests among the three groups; †Paired *t*-tests between the preoperative measurement and the measurements at 6 and 12 months, respectively; ‡Kruskal-Wallis tests among the three groups at 6 and 12 months, respectively; §Statistical significance was established if *p* < 0.05 (paired *t*-test) or *p* < 0.017 (Kruskal-Wallis test).